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Inadequate Evidence to Support Phase
III Studies of Albumin in Severe
Malaria
Charles J. Woodrow, Timothy Planche
The study on severe malaria by Akech et al. [1] found no
signiﬁcant difference between albumin and Gelofusine in any
outcome measure, yet the authors reject further investigation
of Gelofusine and propose phase III studies of albumin as a
neuroprotective agent potentially capable of reducing
mortality in severe malaria by over 80% [2]. Several issues
related to study design and interpretation require
reconsideration of the authors’ main conclusions.
Study design did not incorporate allocation concealment, a
major omission that can inﬂuence patient recruitment at all
stages from case ﬁnding strategy to consent [3]. Figure 1 gives
the impression that patients were randomised after eligibility
assessment, whereas in reality their treatment was known in
advance. Comparison of baseline data for albumin and
Gelofusine groups is an insensitive way to detect enrolment
bias with these numbers of patients. An additional problem
arises from a separate interventional study with phenytoin
conducted simultaneously in comatose children, but no
information is provided about possible interactions with
ﬂuid interventions. The task of undertaking two independent
interventions in the same population would have beneﬁted
from prospective evaluation, for example, using a factorial
design to minimise confounding.
Both intention to treat (ITT) and per protocol (PP) analyses
are presented, with ITT including patients enrolled as an
emergency who did not meet inclusion criteria. In isolation,
this approach may appear reasonable but in similar previous
studies Newton’s group excluded such patients from all
analyses. Given that two of four patients not meeting
inclusion criteria but entering the Gelofusine arm
subsequently died (versus zero of four in the albumin arm),
has the decision to include such patients on this occasion been
taken post hoc since it favoured albumin? The ITT analysis is
quoted selectively at certain points, e.g., while Table 4 shows a
mortality rate of 10% with Gelofusine (PP analysis), the ITT
ﬁgure of 16% is reported in the text and press release. Table 3
describes deaths (eight for Gelofusine, not seven as reported
throughout the text) without reference to patients failing
inclusion criteria; we assume that these ‘‘out of criteria’’
deaths are cases 2 and 10. If so, the short time between
admission and death (1 h and 3 h) suggests that these patients
were moribund at presentation. The potential for bias to
inﬂuence enrolment of these patients (see above), or the
decision to include such patients in the ITT analysis, is evident.
Unfortunately, the editorial commentary compounds
interpretative difﬁculties by incorrectly stating: ‘‘Death
rates in hospital were lower in the group given albumin,
and this was statistically signiﬁcant.’’ Gelofusine was not
associated with a signiﬁcant increase in mortality compared
to albumin (even by ITT analysis). Justiﬁcation for albumin’s
superiority over Gelofusine is instead based on a small ‘‘meta-
analysis’’ of studies of albumin versus ‘‘other ﬂuids’’, the
dominant study of which enrolled 150 patients with 11 saline
and two albumin deaths [4] (an alternative interpretation that
large volumes of saline are hazardous has been discussed [5]).
With only 80 patients enrolled in the Gelofusine versus
albumin study, the ‘‘meta-analysis’’ was highly likely to
generate the same result as its dominant study. We calculate
that this albumin versus Gelofusine study could have had
equivalent mortality in the two arms (up to 10 deaths per arm),
yet the ‘‘meta-analysis’’ would still have showed signiﬁcant
beneﬁt for albumin. Furthermore, there are discrepancies
between the original studies and the ‘‘meta-analysis’’ both in
total number of patients and deaths attributed to saline/
Gelofusine (described, along with other inconsistencies, in our
e-letter on the PLoS Clinical TrialsWeb site [http://clinicaltrials.
plosjournals.org/perlserv/?request¼read-response&doi¼10.
1371/journal.pctr.0010021#r1317]).
Based on these data, as well as preliminary studies of
albumin as a neuroprotective agent in stroke, the authors
now propose a phase III study with albumin, saline, and
maintenance-only arms. This would again test two separate
hypotheses simultaneously (volume resuscitation and brain
protection), and ignores the possibility that saline may be
dangerous [5]. If the authors are committed to studies of
albumin as a neuroprotective agent, an appropriate
development plan should include a prospective, randomised
phase II trial of albumin versus maintenance-only ﬂuid in
patients with cerebral malaria, with speciﬁc monitoring for
adverse events (particularly pulmonary oedema), as for
studies of albumin in stroke [6].
The accompanying article providing support [7] for the
authors’ call for phase III studies has not clariﬁed these issues.
Complicated and important ﬁelds of research demand
corresponding rigour. Phase III mortality studies ought to
be based on appropriately designed and adequately powered
phase II trials with close regard to safety. “
Charles J. Woodrow (cwoodrow@sgul.ac.uk)
Timothy Planche
Division of Cellular and Molecular Medicine
St. George’s University of London
London, United Kingdom
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Phase III Trials Required to Resolve
Clinical Equipoise over Optimal Fluid
Management in Children with Severe
Malaria
Kathryn Maitland, Samuel Akech, Samson Gwer,
Richard Idro, Greg Fegan, Alice C. Eziefula,
Michael Levin, Charles R. J. C. Newton
There is a consensus among paediatricians that outcome of
children presenting with life-threatening infections,
irrespective of the infecting pathogen, can be improved by
timely recognition and prompt intervention to correct
disordered physiology using simple approaches to
resuscitation [1–3]. These approaches include the provision
of oxygen and the correction of ﬂuid, electrolyte, and glucose
deﬁcits [4,5]. Indeed, studies have shown that most of the
recent gains in survival of children with severe infections
have come through the application of this approach by non-
specialists during the initial hours of management [6,7].
Correction of hypotension and volume depletion through
ﬂuid administration is a fundamental component of
resuscitation in most critically ill children [8,9], but its role
in severe malaria remains uncertain and thus represents one
of the most important theoretical gaps in our understanding
of supportive treatments in this condition.
Many children with severe malaria have signs of cardio-
vascular compromise or compensated shock on presentation
to hospital and a smaller proportion are hypotensive [10].
One of the major unresolved aspects of management is
whether volume expansion should be undertaken in children
displaying signs of compensated shock, as is recommended in
other paediatric disorders. Intravascular volume depletion
(hypovolaemic shock) results in impaired cardiovascular
function and inadequate tissue and organ perfusion, and
would usually be corrected rapidly. Simple dehydration,
predominantly affecting the intracellular compartment, can
be safely corrected gradually. The choice of the optimum
ﬂuid for resuscitation is also unclear. Colloidal solutions,
although more costly, are less likely to precipitate cerebral
and pulmonary oedema due to their oncotic properties.
Recognising the importance of adequate ﬂuid management
to the outcome of the critically ill child, the group at Kiliﬁ has
conducted a staged series of studies over the last 15 years to
address each of these questions. In a collaboration that
included specialists in paediatric intensive care, neurology,
and clinical trials, the group demonstrated the importance,
prognostic implications [11], and clinical correlates of
metabolic acidosis in children with severe malaria [12] and
provided clear evidence of intravascular hypovolaemia by
using standard methods for studying critical illness [13]. We
have undertaken two randomised trials to assess the safety of
and response to volume expansion, and to determine whether
colloid replacement offers any advantage over crystalloid
replacement [13,14]. We hypothesised that administration of
colloids such as human albumin solution with volume
expansion would help to retain ﬂuid in the intravascular
compartment and may also improve endothelial function. In
each of these trials we observed that albumin administration
was associated with a lower mortality than saline. Although
this data suggested the need for a large clinical trial of
albumin, in view of the cost of albumin we thought that
cheaper synthetic colloids should be assessed before
embarking on a phase III trial. The intention in the small
phase II trial, recently published in PLoS Clinical Trials [15],
was to provide sufﬁcient physiological data on succinylated
gelatin to inform the design of the next phase, rather than to
establish statistical superiority of one colloid over the other.
For this purpose the trial was most instructive. Again we
observed the same beneﬁts of albumin: only one child who
received albumin died, out of a group of participants that
included children treated as emergencies who were
subsequently found to be ineligible for the trial. The results
for Gelofusine, however, were not encouraging. The
combined ﬁndings that death, severe allergic reaction, and
acute neurological events were more common in the
Gelofusine group suggested that albumin, rather than a
cheaper substitute, should be taken forward into the next
phase. This was supported by the analysis of the combined
data from three trials, including 238 children receiving
volume expansion. While this small phase II study was not
powered to prove that Gelofusine was superior to saline or
albumin, the results suggest that Gelofusine is unlikely to
offer any advantage over the cheaper saline solution.
Given the continued controversy over the use of
resuscitation ﬂuids in the management of severe malaria,
we suggest that this can only be resolved through a deﬁnitive
clinical trial. Woodrow and Planche [16] have chosen a
different interpretation. The evidence presented from two
studies conducted in Gabon, one which assessed volume
depletion in only 12 survivors [17] and the other larger study
conducted in less critically unwell children [18], supports a
position of equipoise—the basis which usually prompts the
need for a deﬁnitive clinical trial. “
Kathryn Maitland (kmaitland@kilifi.kemri-wellcome.org)
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Samson Gwer
Richard Idro
Greg Fagan
Alice C. Eziefula
Charles R. J. C. Newton
Center for Geographic Medicine Research (Coast), Kenya Medical Research
Institute, Kilif, Kenya
Michael Levin
Department of Pediatrics and Wellcome Trust Centre for Clinical Tropical Medicine,
Faculty of Medicine, Imperial College, London, United Kingdom
www.plosclinicaltrials.org February | 2007 | e4 | e20002
........................................................................................
References
1. Mackway-Jones K, Molyneux EM, Phillips B, Wieteska Seditors (2004)
Advanced paediatric life support: The practical approach. London: BMJ
Publishing Group.
2. European Resuscitation Council 2000 Pediatric Life Support Working
Group (2002) Guidelines of the European Resuscitation Council 2000 for
advanced pediatric life support. A statement of the Pediatric Life Support
Working Group following approval by the executive committee of the
European Resuscitation Council. Anaesthesist 51: 406–408.
3. Zaritsky A, Nadkarni V, Hickey R (2002) Pediatric advanced life support
provider manual. Dallas (TX): American Heart Association.
4. Carcillo JA, Fields AI (2002) Clinical practice parameters for hemodynamic
support of pediatric and neonatal patients in septic shock. Crit Care Med
30: 1365–1378.
5. Goldstein B, Giroir B, Randolph A (2005) International pediatric sepsis
consensus conference: Deﬁnitions for sepsis and organ dysfunction in
pediatrics. Pediatr Crit Care Med 6: 2–8.
6. Han YY, Carcillo JA, Dragotta MA, Bills DM, Watson RS, et al. (2003) Early
reversal of pediatric-neonatal septic shock by community physicians is
associated with improved outcome. Pediatrics 112: 793–799.
7. Booy R, Habibi P, Nadel S, de Munter C, Britto J, et al. (2001) Reduction in
case fatality rate from meningococcal disease associated with improved
healthcare delivery. Arch Dis Child 85: 386–390.
8. Carcillo JA, Davis AL, Zaritsky A (1991) Role of early ﬂuid resuscitation in
pediatric septic shock. JAMA 266: 1242–1245.
9. Wills BA, Nguyen DM, Ha TL, Dong TH, Tran TN, et al. (2005) Comparison
of three ﬂuid solutions for resuscitation in dengue shock syndrome. N Engl
J Med 353: 877–889.
10. Maitland K, Levin M, English M, Mithwani S, Peshu N, et al. (2003) Severe P.
falciparum malaria in Kenyan children: Evidence for hypovolaemia. QJM 96:
427–434.
11. Marsh K, Forster D, Waruiru C, Mwangi I, Winstanley M, et al. (1995)
Indicators of life-threatening malaria in African children. N Engl J Med
332: 1399–1404.
12. English M, Waruiru C, Amukoye E, Murphy S, Crawley J, et al. (1996) Deep
breathing in children with severe malaria: Indicator of metabolic acidosis
and poor outcome. Am J Trop Med Hyg 55: 521–524.
13. Maitland K, Pamba A, Newton CR, Levin M (2003) Response to volume
resuscitation in children with severe malaria. Pediatr Crit Care Med 4: 426–
431.
14. Maitland K, Pamba A, English M, Peshu N, Marsh K, et al. (2005)
Randomized trial of volume expansion with albumin or saline in children
with severe malaria: Preliminary evidence of albumin beneﬁt. Clin Infect
Dis 40: 538–545.
15. Akech S, Gwer S, Idro R, Fegan G, Eziefula AC, et al. (2006) Volume
expansion with albumin compared to Gelofusine in children with severe
malaria: Results of a controlled trial. PLoS Clin Trials 1: e21. doi:10.1371/
journal.pctr.0010021
16. Woodrow C, Planche T (2007) Inadequate evidence to support phase III
studies of albumin in severe malaria. PLoS Clin Trials 2: e04. doi:10.1371/
journal.pctr.0020004
17. Planche T, Onanga M, Schwenk A, Dzeing A, Borrmann S, et al. (2004)
Assessment of volume depletion in children with malaria. Plos Med 1: e18.
doi:10.1371/journal.pmed.0010018
18. Jarvis JN, Planche T, Bicanic T, Dzeing-Ella A, Kombila M, et al. (2006)
Lactic acidosis in Gabonese children with severe malaria is unrelated to
dehydration. Clin Infect Dis 42: 1719–1725.
Citation: Maitland K, Akech S, Gwer S, Idro R, Fegan G, et al. (2007) Phase III trials
required to resolve clinical equipoise over optimal fluid management in children
with severe malaria. PLoS Clin Trials 2(2): e2. doi:10.1371/journal.pctr.0020002
Copyright:  2007 Maitland et al. This is an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author
and source are credited.
Funding: The authors received no specific funding for this article.
Competing Interests: The authors have declared that no competing interests
exist.
_____________________________________________________________________
Phase III Trial of Albumin in Malaria
Still Lacks Scientific Justification
Charles J. Woodrow, Timothy Planche
We wrote to PLoS Clinical Trials [1] following the publication
of the article by Akech et al. [2] in order to highlight speciﬁc
problems in the design and analysis of the study presented,
point out errors in the presentation of the data, and seek
clariﬁcation over certain details. As a consequence of this letter
an erratum [3] to the editorial commentary has been issued
conﬁrming that no difference was found in death rate or any
other outcome measure between the two arms of this study.
The authors’ follow-up letter [4] reiterates claims
concerning the beneﬁt of albumin over other ﬂuids,
including Gelofusine. Unfortunately, this letter missed an
opportunity to clarify a number of issues and perpetuates a
number of inaccuracies. For example, the notion of albumin’s
superiority over Gelofusine (groundless given the lack of
statistical evidence for this; see erratum) persists in the
statement beginning: ‘‘The combined ﬁndings that death,
severe allergic reaction, and acute neurological events were
more common in the Gelofusine group. . .’’ Similarly, the
erroneous total patient number included in the meta-analysis
(238) is still used in preference to the correct number (239).
Phase III studies must be based on speciﬁc and relevant
phase II studies. These preferably assess intervention versus
standard treatment (‘‘maintenance-only’’ ﬂuids in most
African hospitals) and optimise dosing strategy while
rigorously and proactively noting adverse events (e.g.,
pulmonary oedema by chest radiography [5]). However,
none of the studies on albumin performed in Kiliﬁ have
incorporated these elements into their design and reported
adverse events in a standardised fashion [5]. Even the
amounts of ﬂuid actually received by patients in the most
recent study are not provided [2]. Comparison of case fatality
rates with historical controls cannot provide the required
safety data to underpin a phase III study. Additionally, given
the lack of a clear hypothesis (the authors discuss albumin
acting in both volume expanding and neuroprotective
capacities), the group of patients who might beneﬁt from
albumin remains uncertain.
Failure to address any of the speciﬁc points in our letter
impairs the ability of readers to review primary data for
themselves. Repeating arguments for phase III studies on
albumin in severe malaria does not make them more
compelling. “
Charles J. Woodrow (cwoodrow@sgul.ac.uk)
Timothy Planche
Division of Cellular and Molecular Medicine
St. George’s University of London
London, United Kingdom
References
1. Woodrow CJ, Planche T (2007) Inadequate evidence to support phase III
studies of albumin in severe malaria. PLoS Clin Trials 2: e04. doi:10.1371/
journal.pctr.0020004
2. Akech S, Gwer S, Idro R, Fegan G, Eziefula AC, et al. (2006) Volume
expansion with albumin compared to Gelofusine in children with severe
malaria: Results of a controlled trial. PLoS Clin Trials 1: e21. doi:10.1371/
journal.pctr.0010021
3. (2006) Correction: Volume expansion with albumin compared to
Gelofusine in children with severe malaria: Results of a controlled trial.
PLoS Clin Trials 1: e37. doi:10.1371/journal.pctr.0010037
4. Maitland K, Akech S, Gwer S, Idro R, Fegan G, et al. (2007) Phase III trials
required to resolve clinical equipoise over optimal ﬂuid management in
children with severe malaria. PLoS Clin Trials 2: e02. doi:10.1371/journal.
pctr.0020002
5. Ginsberg MD, Hill MD, Palesch YY, Ryckborst KJ, Tamariz D (2006) The
ALIAS Pilot Trial: A dose-escalation and safety study of albumin therapy
for acute ischemic stroke—I: Physiological responses and safety results.
Stroke 37: 2100–2106.
www.plosclinicaltrials.org February | 2007 | e2 | e10003
........................................................................................
Citation: Woodrow CJ, Planche T (2007) Phase III trial of albumin in malaria still
lacks scientific justification. PLoS Clin Trials 2(2): e1. doi:10.1371/
journal.pctr.0020001
Copyright:  2007 Woodrow and Planche. This is an open-access article
distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided
the original author and source are credited.
Funding: The authors received no specific funding for this article.
Competing Interests: The authors have declared that no competing interests
exist.
www.plosclinicaltrials.org February | 2007 | e10004
